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Summary
Human T cell leukemias can arise from oncogenes activated by specific chromosomal translocations involving the T cell
receptor genes. Here we show that five different T cell oncogenes (HOX11, TAL1, LYL1, LMO1, and LMO2) are often
aberrantly expressed in the absence of chromosomal abnormalities. Using oligonucleotide microarrays, we identified
several gene expression signatures that were indicative of leukemic arrest at specific stages of normal thymocyte develop-
ment: LYL1 signature (pro-T), HOX11 (early cortical thymocyte), and TAL1 (late cortical thymocyte). Hierarchical clustering
analysis of gene expression signatures grouped samples according to their shared oncogenic pathways and identified
HOX11L2 activation as a novel event in T cell leukemogenesis. These findings have clinical importance, since HOX11
activation is significantly associated with a favorable prognosis, while expression of TAL1, LYL1, or, surprisingly, HOX11L2
confers a much worse response to treatment. Our results illustrate the power of gene expression profiles to elucidate
transformation pathways relevant to human leukemia.
Introduction 2000; Rivera et al., 1991). Securing further advances in treatment
outcome will likely prove difficult without improved knowledge
of the factors that contribute to the malignant behavior of trans-T cell acute lymphoblastic leukemia (T-ALL) is a malignant dis-
formed thymocytes. Unfortunately, most of the clinical and labo-ease of thymocytes, accounting for 10%–15% of pediatric and
ratory features that guide therapy for B cell precursor ALL are25% of adult ALL cases. Patients with T-ALL tend to present
only marginally useful in T-ALL (Pullen et al., 1999).with very high circulating blast cell counts, mediastinal masses,
Current understanding of the molecular basis of T-ALL hasand central nervous system involvement. The prognosis of
come largely from analysis of recurrent chromosomal transloca-T-ALL in children and adolescents has improved in recent years
tions and intrachromosomal rearrangements. These abnormali-due to intensified therapies, with 5 year relapse-free survival
ties typically juxtapose strong promoter and enhancer elementsrates now in the range of 60%–75% (Pui and Evans, 1998;
Silverman et al., 2001; Chessells et al., 1995; Schrappe et al., responsible for high levels of expression of T cell receptor genes
S I G N I F I C A N C E
Careful analysis of clonal chromosomal abnormalities in leukemic blast cells has been a catalyst for the development of new
diagnostic and therapeutic strategies. However, this line of research has had a much greater impact on the B lineage leukemias
than on T cell acute lymphoblastic leukemia (T-ALL), whose pathogenesis and molecular subtypes remain largely undefined. Using
a combination of DNA microarray and RT-PCR methods to analyze clinical T-ALL samples, we obtained results in support of our central
hypothesis that aberrant activation of certain key transcription factor genes, often in the absence of chromosomal rearrangements, is
the principal transforming event in this disease. These developmentally important molecules are shown to drive a limited number
of oncogenic pathways with prognostic significance. The ability to classify T-ALL according to shared pathways of leukemic transforma-
tion has important implications for future research. It provides a conceptual framework in which to identify specific genes that
determine treatment responsiveness and should foster the development of successful new therapies directed to critical molecules
in pathologic transcriptional cascades. The hypothesis-driven approach to microarray analysis described in this report may also be
useful for the study of other types of human cancers.
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next to a small number of developmentally important transcrip- mosome band 1p32 that are known to cause aberrant expres-
sion of TAL1 in T-ALL. However, 9 (31%) of the 29 cases withtion factor genes, including HOX11/TLX1, TAL1/SCL, TAL2,
LYL1, BHLHB1, LMO1, and LMO2 (Finger et al., 1989; Xia et increased expression of TAL1 (Figure 1B) had the Tal1d variant,
which results from a small deletion next to the TAL1 locus (Aplanal., 1991; Mellentin et al., 1989; Wang et al., 2000; McGuire et
al., 1989; Royer-Pokora et al., 1991; Dube et al., 1991; Hatano et al., 1990; Bernard et al., 1991). Thus, the majority of cases
with high levels of TAL1 oncogene expression (22/29) lackedet al., 1991; Fitzgerald et al., 1991; Kennedy et al., 1991; Lu et
al., 1991; Brown et al., 1990; Aplan et al., 1991, 1992; Baer, cytogenetic or molecular evidence of rearrangements affecting
the TAL1 locus, in agreement with results of an earlier study1993; Begley et al., 1989; Chen et al., 1990; Greenberg et al.,
1990; Boehm et al., 1991), resulting in their aberrant expression (Bash et al., 1995).
Thirteen (22%) of the 59 cases were classified as LYL1in developing thymocytes. Although the oncogenicity of these
proteins is well established (Larson et al., 1994; Neale et al., (Figure 1C) on the basis of LYL1 expression levels that exceeded
the mean value in normal thymocytes by more than 5-fold.1995; McGuire et al., 1992; Chervinsky et al., 1999; Condorelli
et al., 1996; Kelliher et al., 1996; Hawley et al., 1997), under- Increased expression of this oncogene was not associated with
cytogenetic abnormalities affecting the LYL1 locus (19p13), con-standing of the downstream transcriptional programs that gen-
erate and maintain the T-ALL phenotype remains limited. Further sistent with the paucity of reports on LYL1 activation by chromo-
somal translocation. Thus, other mechanisms appear responsi-improvement of risk-based treatment strategies and the devel-
opment of effective new drugs for T-ALL will depend on fresh ble for the aberrant expression of LYL1 in thymic leukemias.
Finally, TAL2 and BHLHB1 were expressed at high levels in ainsights into the molecular pathways usurped by HOX11, TAL1,
and other oncoproteins in developing thymocytes. single case each (Figure 1C). Again, cytogenetic analysis failed
to reveal locus-specific translocations associated with the ex-
pression of these oncogenes. Some cases overexpressed moreResults
than one of the closely related bHLH T cell oncogenes: six
overexpressed both TAL1 and LYL1, and one overexpressedOncogenic transcription factor expression in T-ALL
HOX11, an orphan homeobox gene essential for splenic devel- TAL1 and BHLHB1.
Analysis of the LIM-only domain genes LMO1 and LMO2opment (Roberts et al., 1994; Dear et al., 1995), is activated
in a subset of T-ALL cases bearing the t(10;14)(q24;q11) or (Figure 1D) showed an absence of significant expression of
either LMO gene in the HOX11 samples. However, overexpres-t(7;10)(q35;q24), each of which places HOX11 under the control
of strong enhancers embedded in the T cell receptor loci. Acting sion of one of these genes was observed in most samples
overexpressing TAL1, and high levels of LMO2, but not LMO1,on the hypothesis that HOX11 might be aberrantly expressed
in cases other than those harboring locus-specific transloca- were found in the LYL1 samples. These results are consistent
with biochemical and transgenic animal model studies showingtions, we used quantitative real-time reverse transcriptase PCR
(RT-PCR) to analyze HOX11 expression, detecting high levels that LMO proteins form heterocomplexes and act in concert
with TAL1 and possibly other bHLH proteins in T-ALL (Valge-of this oncogene in 8 of 59 pediatric T-ALL samples (Figure 1A).
Four of the HOX11-positive cases had cytogenetic abnor- Archer et al., 1994; Wadman et al., 1994; Larson et al., 1996;
Chervinsky et al., 1999; Herblot et al., 2000; Wadman et al.,malities involving the HOX11 locus in chromosome band
10q24: two t(10;14)(q24;q11.2), one t(7;10)(q35;q24), and one 1997). Ten of the 59 cases (samples 48–51, 53–57, and 59,
Figure 1) did not express abnormal levels of any of the transcrip-del(10)(q24q26). Reduced levels of HOX11 expression (100–
1000 times lower than in the eight HOX11 samples) were de- tion factor genes described above, raising the possibility of
thymocyte transformation via alternative oncogenic mecha-tected in four additional samples, two of which also had cytoge-
netic abnormalities of band 10q24 [t(10;14) and add(10)(q24)]. nisms.
The remaining cases and eight normal control thymus samples
showed only background levels of HOX11 expression, near the Gene expression profiles and their biologic correlates
T cell development is a tightly regulated multistep process thatlimit of detection with this technique. Thus, by using quantitative
RT-PCR analysis of the HOX11 gene, we identified a substantial involves the intrathymic differentiation, proliferation, and selec-
tion of T cell precursors (Murre, 2000; Rodewald and Fehling,proportion of HOX11 cases that express high levels of the
oncogene while lacking cytogenetically detectable alterations 1998). Leukemic thymocytes retain many of the biologic features
of normal T cell precursor subpopulations, as illustrated byof the 10q24 region.
Prominent among T cell oncoproteins are members of the shared patterns of cell surface protein expression (Reinherz and
Schlossman, 1980; Bene et al., 1995). We therefore postulatedbasic helix-loop-helix (bHLH) family of transcription factors:
TAL1, TAL2, LYL1, and the recently described BHLHB1 protein that HOX11, TAL1, and LYL1 overexpression might directly or
indirectly interfere with transcriptional networks that normally(Bernard et al., 1990; Finger et al., 1989; Xia et al., 1991; Mellen-
tin et al., 1989; Wang et al., 2000). These transcriptional regula- regulate thymocyte proliferation, differentiation, and survival
during T cell development (Look, 1997). To test this hypothesis,tors are believed to act through a common mechanism involving
dominant negative interference with the activities of the E47 we used oligonucleotide microarrays (Affymetrix, HU6800) to
analyze the global patterns of gene expression in 39 of theand E12 variants of E2A transcription factors (Begley and Green,
1999; Wang et al., 2000; Miyamoto et al., 1996; Hsu et al., 1994; T-ALL samples with sufficient RNA for these studies (Golub et
al., 1999). The microarray data are available in their entirety asPark and Sun, 1998), whose homozygous inactivation leads
to T cell tumors in mice (Bain et al., 1997; Yan et al., 1997). Supplemental Data at http://www.genome.wi.mit.edu/mpr and
http://www.cancercell.org/cgi/content/full/1/1/75/DC1.Quantitative RT-PCR analysis revealed increased levels of TAL1
mRNA in 29 (49%) of the 59 cases (Figure 1B). None of these We first asked whether the results obtained from microarray
hybridizations agreed with the quantitative RT-PCR findingssamples harbored any of the recurrent translocations of chro-
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Figure 1. Quantitative RT-PCR analysis of oncogenic transcription factor genes in pediatric T-ALL samples and normal thymus controls
A: HOX11 expression. Samples with expression levels 1  105 mRNA copies/100 ng of RNA (dotted line) were considered HOX11. Cases with abnormalities
of chromosome band 10q24 are indicated with arrows.
B: TAL1 expression. Crosshatched bars indicate samples with the Tal1d variant band in 1p32, resulting from deletion of a 90 kb genomic DNA fragment
adjacent to the TAL1 locus. Samples showing TAL1 expression levels above that detected in TAL1d samples were considered TAL1 (dotted line).
C: Expression of LYL1 (yellow bars) and other bHLH transcription factor genes (TAL2 and BHLHB1) (green bars). The threshold level for LYL1 positivity (dotted
line) corresponds to five times the mean level of expression in normal thymus control samples.
D: Expression of LMO1 (purple bars) and LMO2 (orange bars). The threshold level for LMO1 and LMO2 positivity (dotted line) corresponds to five times the
mean level of LMO2 expression in normal thymus control samples. Oval symbols in panels A, B, and C indicate cases included in the microarray analysis.
presented in Figure 1. Normalized microarray results, plotted sion of the CD1 (A-E family members), LAR, and CD10 genes
in a pattern resembling that of normal cells undergoing the earlyas increasing intensities of red (positive) or blue (negative) rela-
tive to the mean value, are shown in Figure 2. The first row of cortical stage of thymocyte differentiation (Terstappen et al.,
1992; Terszowski et al., 2001; Rodewald and Fehling, 1998).colored squares in each of the three panels depicts the expres-
sion levels of HOX11 (top), TAL1 (middle), or LYL1 (bottom) Many of the genes associated with HOX11 expression are in-
volved in cell growth and proliferation. These include adenosineamong the 27 cases independently expressing one of the three
major oncogenes. The cases are arranged in the same order deaminase (target of pentostatin, fludarabine, and 2-chloro-
deoxyadenosine), DNA topoisomerase (target of the anthracy-used to display the quantitative RT-PCR data. There was re-
markable overall agreement between gene expression values clines and epipodophyllotoxins), dihydrofolate reductase (target
of methotrexate), hypoxanthine phosphoribosyltransferase 1obtained by these two methods.
We next surveyed genes considered to be “nearest neigh- (modifier of the effect of antimetabolite therapy), and thymidylate
synthetase (target of fluoropyrimidines and other novel folate-bors” (Golub et al., 1999) of HOX11, TAL1, and LYL1, based
on the close agreement of their expression profiles. Analysis of based inhibitors). The gene products DNA polymerase epsilon,
cyclin A, Tax1 binding protein, and replication protein A1 allthe resultant gene expression signatures (Figure 2) revealed a
striking concordance with recognized stages of normal thymo- have prominent roles in cell proliferation. These findings are
consistent with data showing that HOX11 can both immortalizecyte development (Figure 3). Similar findings have been reported
for B lineage tumors studied with cDNA microarray technology hematopoietic progenitors (Keller et al., 1998) and interact di-
rectly with cell cycle regulatory proteins (Kawabe et al., 1997).(Allzadeh et al., 2000). HOX11 cases showed increased expres-
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For example, high levels of HOX11 correlated with increased
expression of MYC and the proapoptotic glucocorticoid recep-
tor gene. TAL1 overexpression was associated with the upregu-
lation of proto-oncogenes such as CBFA2 (AML1) and the MYB-
related gene MYBL2, receptor genes such as IL8R and CSFR1,
and the antiapoptotic gene BCL2A1. Finally, LYL1 positivity was
related to higher expression levels of the MYCN, LMO2, and
PLZF proto-oncogenes, as well as the antiapoptotic gene BCL2.
Most antineoplastic drugs are thought to act through the mito-
chondrial apoptotic machinery, and their cytostatic effects are
inhibited by BCL2 and its related prosurvival family members
(Reed, 1995). Thus, the upregulation of BCL2 and BCL2A1 in
LYL1- and TAL1-overexpressing cases may explain their relative
resistance to chemotherapy (see Figure 5), while the exquisiteFigure 3. Correlation of gene expression profiles in LYL1, HOX11, and TAL1
responsiveness of HOX11 cases could partly reflect the down-T-ALL samples with recognized stages of thymocyte differentiation
regulation of survival factors in early cortical stage thymocytes,Cell surface markers normally associated with each developmental stage
most of which are targeted for “death by neglect.”(Murre, 2000) are indicated in black, with corresponding microarray findings
shown in red. The most immature T cell precursors express CD34 but not
CD4, CD8, or CD3. As these cells mature, they lose CD34 expression while Hierarchical clustering of T-ALL cases based on gene
gaining CD4 and then CD8, becoming double-positive thymocytes. Early
expression patternsdouble-positive cells initially express CD1 and CD10 (early cortical thymo-
Although helping to identify the sets of genes coordinately ex-cytes). As they finish rearranging their T cell receptor genes, 95% of these
cells fail to express a functional receptor and are ablated through a death- pressed with HOX11, TAL1, and LYL1, the nearest neighbor
by-neglect mechanism. Thymocytes with functional T cell receptors gain analysis depicted in Figure 2 provided little useful information
CD3 expression (late cortical thymocytes) and undergo both positive and
about the 10 cases that lacked discernible expression of thesenegative selection. Cells surviving this process proceed through a final step
oncogenes (designated Other in Figure 4) or the two additionalof differentiation in which they downregulate the expression of either CD4
or CD8 to become mature single-positive T cells. cases expressing both LYL1 and TAL1 (Mixed). To gain insight
in the molecular characteristics of these poorly understood
cases, we generated hierarchical clusters based on the 72 genes
whose expression patterns best distinguished between each
Because the drugs used to treat human leukemias are more group of HOX11, TAL1, LYL1, and other cases in pairwise
active in proliferating cells, these findings may explain in part comparisons (as defined by the permutation distribution of the
the better prognosis of patients with HOX11 T-ALL (see Fig- maximum t statistic, P  0.30).
ure 5). As shown in Figure 4, the HOX11, TAL1, and LYL sam-
By contrast, the expression pattern associated with TAL1 ples detected by RT-PCR are grouped together within major
expression appeared to reflect the late cortical stage of thymo- branches of the dendrogram. The branch containing the HOX11
cyte differentiation, as indicated by the upregulation of LCK, samples (H) comprises two subgroups, one containing most of
TCRA, TCRB, CD2, CD6, and CD3E (Terstappen et al., 1992; the HOX11 RT-PCR-positive cases (H1) and the other consisting
Rodewald and Fehling, 1998). High levels of LYL1 expression primarily of HOX11-like samples that lacked HOX11 expression
were associated with an undifferentiated thymocyte phenotype by RT-PCR (H2). Surface immunophenotyping indicated that
characterized by increased expression of the early hematopoi- these subgroups had related but distinct immunophenotypes
etic marker gene CD34, the cell adhesion gene L-selectin (SELL), (Table 1). True HOX11 samples were primarily CD1, CD10/,
the antiapoptotic gene BCL2, and LSP1, which encodes the CD4, CD8, and CD3 (early cortical thymocytes), while the
lymphocyte-specific protein 1 (Pilarski et al., 1991; Galy et al., HOX11-like samples were primarily CD1/, CD10, CD4,
1993; Ma et al., 1995; Palker et al., 1998). These results suggest CD8, and CD3 (early cortical thymocytes with acquired CD3
that T cell oncogenes specifically interfere with transcriptional surface expression). Similarly, the central cluster of TAL1 sam-
programs controlling thymocyte development, leading to stage- ples contained two subgroups, a larger one comprising most
specific developmental arrest. of the true TAL1 samples (T1) and a second consisting mainly
The three molecularly distinct subtypes of T-ALL also of TAL1-like samples (T2). A third, smaller branch (M) emerged
showed specific associations with known proto-oncogenes, as from the hierarchical analysis, and was characterized by a global
pattern of increased expression of many of the genes that distin-well as genes involved in programmed cell death (Figure 2).
Figure 2. HOX11, TAL1, and LYL1 nearest neighbor analysis
Each row of squares shows the expression pattern of a particular gene selected by nearest neighbor analysis (Golub et al., 1999), while each column
represents 1 of the 27 samples positive for HOX11, TAL1, or LYL1 by RT-PCR (see Figure 1). The genes depicted were chosen from the top 200 nearest
neighbors of each major oncogene (boldface type) on the basis of their potential functional relevance and then were grouped according to their
involvement in T cell differentiation, apoptosis, cell proliferation, or chemotherapy response. Expression levels for each gene were normalized across the
samples; levels greater than or less than the mean (by as much as three standard deviations) are shown in shades of red or blue, respectively. Numbers
at the bottom correspond to the numbers of the samples in Figure 1. For a complete list of gene names, accession numbers, and raw expression values,
see Supplemental Data at http://www.genome.wi.mit.edu/mpr and http://www.cancercell.org/cgi/content/full/1/1/75/DC1.
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Figure 4. Hierarchical cluster analysis of gene expression data
Expression profiles of 72 genes were selected by permutation test analysis as those best distinguishing among 39 HOX11, TAL1, LYL1 cases and unclassified
samples (Other). The dendrogram (top) shows the relatedness of gene expression among samples and is color coded according to the quantitative RT-
PCR category of each sample (see Figure 1). Clinical outcome data are reported as horizontal bars with open boxes representing survivors and dark boxes
deceased patients. Cytogenetic and molecular abnormalities are indicated by discrete symbols defined at the bottom of the figure. Each column represents
a T-ALL mRNA sample and each row a gene on the microarray. Genes are grouped into four consecutive categories: higher in HOX11 than in TAL1,
LYL1, or Others; higher in TAL1 than in HOX11, LYL1, or Others; higher in LYL1 than in HOX11, TAL1, or Others; and finally higher in Others than in
HOX11, TAL1, or LYL1; and are listed within each category in order from lowest to highest P value. A complete list of genes and P values is available
as Supplemental Data at http://www.genome.wi.mit.edu/mpr and http://www.cancercell.org/cgi/content/full/1/1/75/DC1. Gene expression values are
normalized and color coded, as indicated by the scale beneath the graph. Major branches in the dendrogram are designated by the first letter of the
dominant oncogene (e.g., H, H1, H2, for HOX11).
guished among the other three groups. Interestingly, two of Finally, the LYL cluster (L) included two branches. One
contained three of the true LYL samples (L1), including thethese three cases had the t(11;19)(q23;p13.3), which produces
the MLL-ENL fusion gene (Rubnitz et al., 1999a), while the re- only T cell sample in this series with the FLT-3 internal tandem
duplication, which is often identified in acute myeloid leukemiasmaining case had a normal karyotype. MLL-ENL RT-PCR analy-
sis, performed in 59 samples, revealed the MLL-ENL fusion (Nakao et al., 1996; Yokota et al., 1997). These leukemias also
expressed high levels of CD34 as well as myeloid markers,transcript in only three cases, all in the M cluster, including the
case with a normal karyotype. This result illustrates the power of consistent with differentiation arrest in the early stages of T cell
development, when T progenitor cells are migrating from theDNA microarray analysis to group samples according to specific
mechanisms of leukemic transformation. bone marrow to the thymus. A second branch (L2) contained
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Table 1. Cell surface antigen expression among T-ALL samples
DPa DNb MYc
CD34 CD10 CD1 CD4 CD8 CD4 CD8 CD3 CD13/33
Cluster H 43 78 75 78 0 36 7
n  14
HOX11 37 62 100 62 0 0 0
In cluster H
n  8
HOX11 50 100 50 100 0 83 16
In cluster H
n  6
Cluster T 71 27 46 73 13 66 0
n  14
Cluster T1 78 20 40 70 20 90 0
n  9
Cluster T2 60 40 60 80 0 20 0
n  5
Cluster L 100 33 0 0 83 33 100
n  6




a LYL sample and two samples with simultaneous expression group of leukemias. HOX11L2, on the other hand, was ex-
pressed at high levels (106 copies per 100 ng of RNA) in sixof TAL1 and LYL1 by quantitative RT-PCR. Indications of
multistep mutational pathways emerged when samples were of the T-ALL samples (29, 48, 49, 51, 54, and 55, as numbered
in Figure 1), but was undetectable in normal thymus and theanalyzed by quantitative DNA PCR for deletions of P16/INK4A-
P14/ARF (Drexler, 1998; Okuda et al., 1995). In our series of other T-ALL samples. Three of the six HOX11L2 cases (closed
triangles in Figure 4) had sufficient RNA for microarray analysis.T-ALL cases, homozygous deletions of this gene were found
in most samples in clusters H and T (Figure 4), which included Their location in the HOX11-related “H2 cluster” of the hierarchi-
cal dendrogram confirms our hypothesis that cases with geneHOX11 and TAL1 cases as well as cases with similar overall
patterns of gene expression. Homozygous deletion of P16/ expression signatures resembling HOX11 cases might be
transformed through the effects of highly related oncogenesINK4A-P14/ARF was not detected in 2 of the three MLL-ENL
cases in the M cluster, nor in any of the cases grouped into operating through similar oncogenic pathways.
Statistical analysis to identify the genes that were differen-cluster L, which comprise LYL1 cases as well as mixed cases
expressing both TAL1 and LYL1 (Figure 4). The exclusive pres- tially expressed in HOX11 versus HOX11L2 cases revealed
increased expression (Permax P value 0.30, see Experimentalence of cytogenetic features such as the 5q- and 13q-deletions
within the L2 subgroup (Figure 4) further attests to the ability Procedures) of HOX11 itself and eight additional genes in
HOX11 cases (Fuse binding protein 2 [FBP2; U69126],of our hierarchical clustering approach to group samples with
common mechanisms of transformation and suggests that tu- DXS9879E [ITBA2; X92896], H2AZ histone [H2AZ; M37583],
glycerladehyde-3-phosphate dehydrogenase [G3PD, ECmor suppressor genes in the 5q and 13q regions are inactivated
as part of a distinct oncogenic pathway that gives rise to these 1.2.1.12; X01677], SW1/SNF complex 155 kDa subunit
[BAF155; U66615], FYN binding protein [FYB; U93049], protea-leukemias.
some subunit  1 [PSMA1; M64992] and tubulin  5 [V00599]).
Oncogene discovery through microarray expression None of the genes on the microarray were expressed at signifi-
analysis: HOX11L2 is activated in T-ALL samples cantly higher levels in HOX11L2 cases. Thus, despite the
The observation that T-ALL leukemia cases with MLL-ENL re- marked similarities in gene expression profiles between HOX11
arrangement and recurrent cytogenetic abnormalities were and HOX11L2 cases, HOX11 cases are distinguished by in-
grouped together in our hierarchical clustering analysis illus- creased expression of genes involved in signal transduction
trates the ability of gene expression profiling to identify cases and the chromatin-mediated control of gene expression (see
with common mechanisms of transformation. Results of this Discussion).
analysis also suggested that cases without defined oncogene
activation that clustered with the HOX11, TAL1, or LYL1 samples Oncogene activation and gene expression signatures
have prognostic relevancelikely harbor related but as yet unidentified oncogenes. To test
this hypothesis, we used quantitative RT-PCR to analyze the To assess the prognostic significance of these findings, we first
analyzed the survival of 58 eligible patients from the 59 whoseexpression of HOX11L1 and HOX11L2, two homeobox genes
that are not included in the Affymetrix 6800 microarray but are leukemic cells were analyzed for HOX11, HOX11L2, TAL1, or
LYL1 expression by quantitative RT-PCR. Preliminary compari-functionally and structurally related to HOX11. HOX11L1 was
expressed at comparable low levels in both normal thymus and son of the Kaplan-Meier plots showed no significant difference
between the TAL1 and LYL1 groups, prompting us to com-T-ALL samples, indicating that it was not overexpressed in this
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achieve complete remission, was noted only in patients with
overexpression of TAL1 or LYL1.
Similar results were obtained when the Kaplan-Meier analy-
sis focused on the major groups defined by hierarchical cluster-
ing of gene expression signatures (Figure 5B): probability of
survival at 5 years was 92% 	 8% for the HOX11 cluster
versus 43% 	 19% and 33% 	 19% for the TAL1 and LYL1
clusters (P 0.03). None of the three patients in the small cluster
containing the MLL-ENL cases have died. Although based on
a small number of samples, this result agrees with a previous
report suggesting that MLL-ENL translocations in T-ALL may
not carry the dire prognosis associated with related transloca-
tions in infants and older children with an early B lineage ALL
immunophenotype (Behm et al., 1996; Rubnitz et al., 1999b).
Discussion
The dramatically different clinical courses of T-ALL patients
treated with the same intensive multidrug regimens support the
interpretation that ALL arising in thymic lymphocytes comprises
several biologically distinct diseases. This variability likely re-
flects a molecular heterogeneity that has not been appreciated
from characterization of leukemic T cells by conventional meth-
ods, as recently demonstrated in a microarray study for diffuse
large B cell lymphoma (Allzadeh et al., 2000). Thus, gene expres-
sion analysis using oligonucleotide or cDNA microarrays offers
a novel tool for delineating molecular pathways that drive the
malignant transformation of developing thymocytes.
The results reported here identify previously unrecognized
molecular subtypes of T-ALL and link the activation of particular
oncogenes to defined stages of normal thymocyte develop-
ment. Highly favorable clinical outcomes were observed for
patients in the HOX11 cluster, whose cell samples showed a
pattern of gene expression resembling that of early cortical
thymocytes. The better therapeutic responsiveness of this sub-
group may be explained by several distinctive features of
HOX11 lymphoblasts, including the expression of genes asso-
ciated with increased cell proliferative activity and the lack of
expression of BCL2 and related antiapoptotic genes. Apoptosis
is a major regulatory mechanism during normal T cell develop-
Figure 5. Clinically important T-ALL subgroups identified by gene expression ment, eliminating the more than 90% of normal cortical thymo-
profiling
cytes unable to express functional T cell receptors (Vacchio et
A: Kaplan-Meier plots of overall survival among patients with a HOX11, al., 1998). Thus, HOX11 lymphoblasts appear to be arrestedHOX11L2, bHLH, or unclassified (Other) gene expression signature by RT-
at a stage of thymocyte development that is especially respon-PCR analysis (TAL1, TAL2, bHLHB1, and LYL1 samples combined as
bHLH). sive to drug-induced programmed cell death.
B: Kaplan-Meier plots of overall survival for subgroups recognized by hierar- Less favorable outcomes were observed in subgroups de-
chical clustering of DNA microarray data, which subdivided the samples fined by gene expression profiles characteristic of TAL1 or
into four main clusters (H, T, M, and L; see Figure 4). Tick marks on the curves
LYL1 samples, which resemble late cortical and early pro-Trepresent surviving patients.
thymocytes, respectively. Drug resistance in LYL samples may
be explained by the fact that early double-negative pro-T cells
express high levels of BCL2 and show increased resistance to
apoptosis (Veis et al., 1993). TAL1 cells appear to upregulatebine these two cohorts (bHLH) for further analysis. As shown
BCL2A1 (also known as BFL1) and other antiapoptotic mole-in Figure 5A, constitutive expression of HOX11 was associated
cules normally induced by signaling through the TCR in latewith a favorable prognosis: probability of survival at 5 years was
cortical thymocytes (Tomayko et al., 1999), suggesting different100% 	 0% standard error (SE), compared with 30% 	 24%
mechanisms of treatment resistance in TAL1 and LYL1 cases.for the HOX11L2 group and 51% 	 9% for the bHLH group
We find it surprising that LYL1 and TAL1 overexpression is(P 0.02 by log-rank analysis, comparing HOX11 with all other
associated with maturational arrest at opposite ends of thepatients). Patients whose leukemic cells lacked expression of
thymocyte developmental spectrum, despite structural and bio-HOX11, HOX11L2, or bHLH oncogenes had essentially the
chemical data suggesting that these two proteins might actsame probability of 5 year survival as the latter two groups (P 
0.81). Primary drug resistance, demonstrated by the failure to quite similarly as inhibitors of normal E12/E47 bHLH activity
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(Murre, 2000; Baer, 1993; Miyamoto et al., 1996). This may would stress, however, that only a small subset of the genes
comprising each gene expression signature are likely to be di-reflect differences in the stages of thymocyte differentiation
at which these oncogenes are activated. Alternatively, the key rectly regulated by the oncogenic transcription factors them-
selves. Since many of the specifically expressed genes appeartransformation event involving bHLH oncogenes may occur
early in the CD4/CD8 cell stage. In this model, TAL1 may to reflect a specific stage of T cell developmental arrest, it will
be important to compare gene expression profiles in leukemicabrogate the normal E2A-induced arrest of further differentiation
(Engel et al., 2001) more effectively than LYL1, leading to leuke- T lymphoblasts versus subsets of normal thymocytes at different
stages of differentiation to identify transcriptional programs thatmias that resemble more mature CD4/CD8 double-positive
thymocytes. are directly linked to leukemic transformation.
Our studies indicate that wider application of gene expres-Our microarray studies of leukemic thymocytes revealed
distinctive gene expression signatures that are strongly associ- sion profiling in T-All would help to identify therapeutically rele-
vant diagnostic subgroups. It may also be possible, given suffi-ated with specific oncogenic transcription factors. In some in-
stances, closely related signatures were found in samples lack- cient numbers of patients, to identify signal transduction
pathways that are vital to the proliferation and survival of individ-ing activation of known T-ALL oncogenes, leading us to predict
alternative oncogenic transcription factors that could initiate ual subgroups, making proteins within these pathways attractive
targets for new therapeutic approaches.similar patterns of gene expression. In experiments based on
this hypothesis, we identified HOX11L2 overexpression as an
Experimental proceduresoncogenic event in HOX11-negative samples that exhibited the
gene expression signature associated with bona fide HOX11-
Patient material
expressing cases. HOX11L2 is an orphan homeobox factor very Samples of cryopreserved lymphoblasts from 59 children and young adults
similar to HOX11, and has been shown to be essential for the with T-ALL, treated in Total Therapy studies XI–XIII at St. Jude Children’s
normal development of the ventral medullary respiratory center, Research Hospital (TN), were obtained with informed consent at the time of
diagnosis, before any chemotherapy was given. The median age of thein that its deficiency in mice leads to a respiratory failure resem-
patients was 9.3 years (range 0.5–18.8), the male to female ratio was 3.0,bling congenital central hypoventilation syndrome in humans
and the leukocyte count at diagnosis was 2,300–917,000 per mm3 (median,(Shirasawa et al., 2000). The recent report by Bernard et al.
164,000). Mean lymphoblast percentage in the samples analyzed was 91%	
(2001) of a novel cryptic recurrent translocation t(5;14)(q35;q32) 10% SD. Six patients had CNS disease at presentation, and mediastinal
in T-ALL resulting in aberrant HOX11L2 expression reinforces masses were present in 36. One case with less than one year of followup
the role of this homeobox factor as a T-ALL oncogene. was excluded from survival analysis. Lymphoid cells were also obtained
(with informed consent) from normal thymic tissue removed at the time ofGiven the marked similarity in gene expression profiles be-
cardiac surgery.tween HOX11 and HOX11L2 cases, it is surprising that these
two groups of patients have such different treatment outcomes,
DNA and RNA preparationand additional patients will need to be studied to confirm this
RNA was prepared from cryopreserved lymphoblasts with RNAqueous re-
result. Of the eight genes that were more highly expressed by agents (Ambion) according to the manufacturer’s instructions and quanti-
HOX11 leukemias, FBP2, BAF155, and FYB encode regulatory tated spectrophotometrically. The quality of the purified RNA was assessed
by visualization of 18S and 28S RNA bands under ultraviolet light afterproteins that might provide insight into the dissimilar clinical
electrophoresis through denaturing agarose gels and staining with ethidiumresponses. The far upstream binding protein 2 (FBP2) regulates
bromide. Genomic DNA from each sample was extracted with a commercialalternative mRNA splicing through binding to intronic splicing
kit (GENTRA) following the manufacturer’s instructions, spectrophotometri-enhancer sequences (Min et al., 1997), while BRG1-associated
cally quantified, and stored at 20
C until analysis.
factor 155 (BAF155) is the human homolog of the yeast protein
SWI3, a component of the SWI/SNF complex that regulates Primers and probes
gene expression through chromatin remodeling. Two compo- Primers and probes were designed with the assistance of the computer
program Primer Express (Perkin-Elmer Applied Biosystems) and with flankingnents of the corresponding mammalian complex, BAF47/SNF5
intron-exon boundaries to prevent amplification from any residual genomic(Roberts et al., 2000; Versteege et al., 1998) and BRG1 (Wong
DNA, while avoiding areas involved in the generation of alternative splicedet al., 2000), are known to be tumor suppressors, and BAF155
mRNAs. In the case of TAL2, BHLHB1, HOX11L1, and HOX11L2, which
together with BRG1 has been shown to interact with cyclin E, lacked suitable intron-exon boundaries for primer-probe design, the amount
with BRG1 specifically causing cell growth arrest (Shanahan et of residual genomic DNA in each sample was determined by simultaneous
al., 1999). FYN binding protein (FYB) is an important positive quantitation of these genes on RNA specimens in the presence and absence
of reverse transcriptase. GAPDH FW: 5-GAAGGTGAAGGTCGGAGT-3,regulator of T cell activation and couples TCR signals to integrin
GAPDH RV: 5-GAAGATGGTGATGGGATTTC-3, GAPDG Probe: 5-VIC-activation and adhesion (Geng et al., 2001; Griffiths et al., 2001;
CAAGCTTCCCGTTCTCAGCC-TAMRA-3, TAL1 FW: 5-GAAGAGGAGAPeterson et al., 2001).
CCTTCCCCCT-3, TAL1 RV: 5-GGTGAAGATACGCCGCACA-3, TAL1In contrast to the inclusive microarray analysis employed
Probe: 5-FAM-TGAGATGGAGATTACTGATGGTCCCCA-TAMRA-3, TAL2
by Allzadeh and coworkers to characterize subgroups of B cell FW: 5-GCCTGCAACAAACGGGAGT-3, TAL2 RV: 5-AGAGTTCTGTCCTC
lymphoma (Allzadeh et al., 2000), we chose to focus genes that CAGGCCT-3, TAL2 Probe: 5-FAM-CTCTTCCCTCAAGGACCCCACCTGC-
best distinguish among cases expressing known T-All onco- TAMRA-3, LYL1 FW: 5-CCCACTTTGGCCCTGCA-3, LYL1 RV: 5-
GGTCCTGCTGGCCCAATGT3, LYL1 Probe: 5-FAM-TACCACCCTCACCgenes. This approach was based on the hypothesis that domi-
CCTTCCTCAACAGTGTC-TAMRA-3 BHLHB1 FW: 5-GGCAGTGGCTTnant oncogenic transcription factors in this disease, such as
CAAGTCGTC-3, BHLHB1 RV: 5-TCCGGCTCTGTCATTTGCTT-3,HOX11, TAL1, and LYL1, stand at the top of regulatory cascades
BHLHB1 Probe: 5-FAM-TCGTCCAGCACCTCGTCGTCTACG-TAMRA-3,whose aberrant activation can lead to T cell neoplasia. Our
HOX11 FW: 5-TGGATGGAGAGTAACCGCAGAT-3, HOX11 RV: 5-
“hypothesis driven” approach to hierarchical clustering has en- GGGCGTCCGGTTCTGATA-3, HOX11 Probe: 5-FAM-CACAAAGGACAG
abled us to integrate complex gene expression patterns into a GTTCACAGGTCACCC-TAMRA-3, HOX11L1 FW: 5-GGATGCTGGGTC
CACACAAC-3, HOX11L1 RV: 5-CAGGATCTGATCGATGCCGA-3,conceptual framework with biologic relevance to T cell ALL. We
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